- Home
- COE vs ANTX Comparison
COE vs ANTX Comparison
Compare COE & ANTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | COE | ANTX |
|---|---|---|
| Founded | 2011 | 2017 |
| Country | Singapore | United States |
| Employees | N/A | N/A |
| Industry | Other Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 140.9M | 129.8M |
| IPO Year | 2015 | 2022 |
Fundamental Metrics
Financial Performance| Metric | COE | ANTX |
|---|---|---|
| Price | $27.99 | $4.69 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $2.00 |
| AVG Volume (30 Days) | 8.1K | ★ 334.8K |
| Earning Date | 06-08-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 32.56 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $15.32 | $1.00 |
| 52 Week High | $56.13 | $6.91 |
Technical Indicators
Market Signals| Indicator | COE | ANTX |
|---|---|---|
| Relative Strength Index (RSI) | 66.65 | 70.62 |
| Support Level | $25.32 | $1.06 |
| Resistance Level | $30.68 | $6.91 |
| Average True Range (ATR) | 1.81 | 0.36 |
| MACD | 0.58 | 0.13 |
| Stochastic Oscillator | 100.00 | 81.23 |
Price Performance
Historical ComparisonAbout COE 51Talk Online Education Group
51 Talk Online Education Group is an online education platform in China, with core expertise in English education. The company's mission is to make quality education accessible and affordable. It's online and mobile education platforms enable students across China to take live interactive English lessons with overseas foreign teachers, on demand. The Group operates in seven principal geographical area: China, Hong Kong, Philippines, Singapore, Malaysia, Thailand and Saudi Arabia.
About ANTX AN2 Therapeutics Inc.
AN2 Therapeutics Inc is a biopharmaceutical company focused on discovering and developing novel small molecule therapeutics derived from its boron chemistry platform. The company has a pipeline of boron-based compounds in development for Chagas disease, non-tuberculous mycobacterial (NTM) and melioidosis, along with early-stage programs focused on targets in infectious diseases and oncology. Product candidate AN2-502998 Epetraborole.